Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early‐stage, favorable Hodgkin lymphoma

@article{Gobbi2003VinblastineBA,
  title={Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early‐stage, favorable Hodgkin lymphoma},
  author={Paolo G. Gobbi and Chiara Broglia and Francesco Merli and Matteo Dell'olio and Caterina Stelitano and Emilio Iannitto and Massimo R Federico and Raffaella Bert{\`e} and Dimitri Luisi and Stefano Molica and Carla Cavalli and Laura Dezza and Edoardo Ascari},
  journal={Cancer},
  year={2003},
  volume={98}
}
The acknowledged effectiveness of vinblastine, bleomycin, and methotrexate (VBM) chemotherapy in patients with early‐stage Hodgkin lymphoma has been associated with conflicting toxicity reports. 
What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma?
TLDR
The very good results, the abated side effects on the lungs, the low extrapulmonary toxicity, and the anthracycline-free formulation make this combination therapy worth considering for early-stage Hodgkin lymphoma, particularly in the case of mediastinal involvement or in elderly patients. Expand
Resection alone in 58 children with limited stage, lymphocyte‐predominant Hodgkin lymphoma–experience from the European network group on pediatric Hodgkin lymphoma
TLDR
To clarify the optimum treatment strategy in children, European study groups were asked to report their experience of surgery alone used in the treatment of pediatric LPHL. Expand
Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
TLDR
Despite the short follow-up, CMT or RT alone tailored according to the clinical prognostic factors were successful in terms of disease control in clinical Stage I-IIA Hodgkin's disease. Expand
Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy
TLDR
The relative tumour burden (rTB) demonstrated to be the best predictor of early failure, outperforming every other pre‐treatment parameter, International Prognostic Score included and safe rTB limits are proposed for successful administration of VBM chemotherapy plus involved‐field radiotherapy. Expand
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
TLDR
HDC seems to be a reasonable option for selected patients with refractory HL, although the majority of them did not receive a transplant, and patients with a high-risk score had little chance of receiving potentially curative treatment. Expand
The cardiotoxicity of chemotherapy: New prospects for an old problem
TLDR
The identification of novel molecular targets will increase the number of drugs available for the treatment of neoplastic disease, and it will be important to evaluate the side effects related to treatment, particularly in organs with a limited regenerative capability such as the heart. Expand
Hodgkin lymphoma.
TLDR
Although some evidence suggests that more intensive combinations provide better disease control, the inevitable increased risk of relevant late toxicity worries investigators. Expand
Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters.
TLDR
The estimated rTB is accurate enough to retain most of the prognostic advantage of the measured rTB over the IPI score, and can be proposed as a useful tool for clinical research and practice. Expand
Classical Hodgkin’s lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
TLDR
Practice guidelines for the initial work-up, therapy and follow-up of classical Hodgkin’s lymphoma are provided to prospectively limit the risk of therapy-related gonadic damage and to preserve fertility. Expand
Natural compounds as a basis for the design of modulators of p53 activity
The present review summarizes data on compounds of natural origin increasing p53 expression in tumor cells. The main focus is on structures containing an indole core.
...
1
2
3
...

References

SHOWING 1-10 OF 31 REFERENCES
Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease.
TLDR
Based upon the current numbers and follow-up, the authors can be 90% confident that VBM as an adjuvant to irradiation in favorable Hodgkin's disease is as effective, or even superior, to MOP(P) chemotherapy. Expand
Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.
  • P. Gobbi, C. Pieresca, +8 authors E. Ascari
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
VBM CT combined with EF RT is an effective treatment for early, clinically staged, favorable HD patients, however, the toxicity of this combination suggests that certain modifications should be evaluated. Expand
Toxicity and response criteria of the Eastern Cooperative Oncology Group
TLDR
The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials. Expand
Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation.
TLDR
VBM serves as a paradigm to reduce late effects in favorable early-stage HD and is encouraged to participate in clinical trials with the objective of maintaining efficacy while reducing toxicity in CS I and II HD. Expand
British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease.
TLDR
There was less toxicity with this regimen although modest acute pulmonary toxicity was still observed, however, in view of the length of treatment with MVP (9 months) and the excellent results reported by the Manchester group, future efforts of the BNLI are to be directed towards a new short course chemotherapy regimen, VAPEC-B. Expand
Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study.
TLDR
VBM with involved-field radiotherapy is an effective treatment for early Hodgkin's disease, however, the associated toxicity, both pulmonary and hematologic, is severe, making the regimen unsuitable for routine use. Expand
Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease.
TLDR
Preliminary data indicate that the VBM regimen provides a safe and effective therapeutic option for elderly patients with untreated Hodgkin's disease. Expand
Treatment of Hodgkin's disease using intensive chemotherapy followed by irradiation.
TLDR
Serious treatment-related morbidity was observed in 15 (54%) of the 28 patients; four of the complications have resulted in death to date with no residual Hodgkin's disease identifiable at autopsy examination. Expand
Pulmonary toxicity of antineoplastic agents
  • M. Green
  • Medicine
  • The Western journal of medicine
  • 1977
TLDR
Pulmonary parenchymal or pleural reactions to chemotherapeutic agents used in the management of patients with malignant diseases are being recognized with increasing frequency and appear to be direct toxic effects of the drugs. Expand
Problems in Hodgkin's disease management.
TLDR
A section of the Hodgkin’s disease mortality curve gives cause for satisfaction with the progress of the past 30 years. Expand
...
1
2
3
4
...